Free Trial

PTC Therapeutics Q4 2023 Earnings Report

PTC Therapeutics logo
$54.24 -0.75 (-1.36%)
As of 03/28/2025 04:00 PM Eastern

PTC Therapeutics EPS Results

Actual EPS
-$0.24
Consensus EPS
$0.29
Beat/Miss
Missed by -$0.53
One Year Ago EPS
N/A

PTC Therapeutics Revenue Results

Actual Revenue
$307.06 million
Expected Revenue
$315.90 million
Beat/Miss
Missed by -$8.84 million
YoY Revenue Growth
N/A

PTC Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

PTC Therapeutics Earnings Headlines

Elon’s ‘Strike Squad’ sends these 9 stocks soaring?
Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the federal government. And that's creating a huge buying opportunity for the stocks involved. Put simply, under Elon's watchful eye, the U.S. government is rapidly adopting AI technology. And that's sending certain stocks soaring higher.
See More PTC Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PTC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PTC Therapeutics and other key companies, straight to your email.

About PTC Therapeutics

PTC Therapeutics (NASDAQ:PTCT), a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

View PTC Therapeutics Profile

More Earnings Resources from MarketBeat